PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Better than RNAZ's estimated revenue of 1.00M.
-1.93M
Worse than RNAZ's estimated ebitda of 0.
-1.38
Better than RNAZ's estimated eps of -45.64.
-41.62M
Worse than RNAZ's estimated net income of -16.25M.
-1.93M
Worse than RNAZ's estimated ebit of 0.
358.54M
Worse than RNAZ's estimated sg&a expense of 0.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Better than RNAZ's revenue of 0.00.
-92.14%
Worse than RNAZ's revenue growth rate of 0.00%.
-51.13M
Worse than RNAZ's ebitda of -17.97M.
-63123.46%
Worse than RNAZ's ebitda margin of 100.00%.
-51.92M
Worse than RNAZ's ebit of -18.49M.
-64098.77%
Worse than RNAZ's ebit margin of 100.00%.
790.00K
Worse than RNAZ's depreciation of 516.75K.
76.68M
Better than RNAZ's total cash of 2.77M.
94662.96%
Better than RNAZ's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Worse than RNAZ's accounts payable of 0.00.
9818.52%
Worse than RNAZ's payables as percentage of revenue of 100.00%.
-153.00K
Better than RNAZ's capital expenditure of -35.61K.
-188.89%
Better than RNAZ's capex as percentage of revenue of 100.00%.
4.99%
Better than RNAZ's weighted average cost of capital (wacc) of 12.20%.
5.02%
Better than RNAZ's cost of equity of 11.27%.
4.08%
Better than RNAZ's cost of debt of 70.02%.
-0.23
Better than RNAZ's beta of 1.53.
30.07M
Worse than RNAZ's diluted shares outstanding of 356.12K.
1.57M
Worse than RNAZ's total debt of 38.29K.
49.31M
Better than RNAZ's total equity of 2.39M.
50.89M
Better than RNAZ's total capital of 2.42M.
3.09%
Worse than RNAZ's debt weighting of 1.58%.
96.91%
Worse than RNAZ's equity weighting of 98.42%.
-51.92M
Worse than RNAZ's ebiat of -18.49M.
-53.46M
Worse than RNAZ's unlevered free cash flow of -21.44M.
2.00%
Equal to RNAZ's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than RNAZ's net debt of -5.77M.
71.33M
Better than RNAZ's equity value of 5.77M.
2.37
Worse than RNAZ's equity value per share of 16.21.